BC Innovations | Jun 28, 2018
Translation in Brief

Against the gradient

In a paper published in Nature Communications , University of Copenhagen researchers identified solute carrier family 12 potassium-chloride transporter member 2 (SLC12A2; NKCC1) as one protein by which CSF is transported into the brain, introducing a...
BC Innovations | Feb 9, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Solute carrier family 12 potassium-chloride transporter member 2 (SLC12A2, NKCC1); p75 neurotrophin receptor (p75 NTR) Studies in mice suggest that bumetanide could help treat...
BC Week In Review | Jan 23, 2012
Company News

Only for Children, Swedish Orphan Biovitrum deal

Only for Children granted Swedish Orphan Biovitrum rights to commercialize bumetanide reformulated to treat diuresis and seizures in neonates. Only for Children is responsible for obtaining market authorizations. Only for Children will receive €300,000 ($380,310)...
BC Week In Review | Nov 24, 1997
Clinical News

Gensia regulatory update

GNSA's Gensia Laboratories Ltd. subsidiary (Irvine, Calif.) received ANDA approval from the FDA for bumetanide injection for the acute treatment of edema associated with congestive heart failure and hepatic and renal disease in patients with...
Items per page:
1 - 4 of 4